Tom P. Marshall

Suggest Changes
Learn More
Context Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event. Objectives To establish whether these benefits(More)
BACKGROUND There are now effective drugs to prevent cardiovascular disease and guidelines recommend their use. Patients do not always choose to accept preventive medication at levels of risk(More)